These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 29343128)

  • 1. Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study.
    Hobart M; Skuban A; Zhang P; Josiassen MK; Hefting N; Augustine C; Brewer C; Sanchez R; McQuade RD
    Curr Med Res Opin; 2018 Apr; 34(4):633-642. PubMed ID: 29343128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.
    Thase ME; Youakim JM; Skuban A; Hobart M; Zhang P; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
    J Clin Psychiatry; 2015 Sep; 76(9):1232-40. PubMed ID: 26301771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Fixed-Dose Brexpiprazole 2 mg/d as Adjunctive Treatment of Adults With Major Depressive Disorder.
    Hobart M; Skuban A; Zhang P; Augustine C; Brewer C; Hefting N; Sanchez R; McQuade RD
    J Clin Psychiatry; 2018 May; 79(4):. PubMed ID: 29873953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.
    Thase ME; Youakim JM; Skuban A; Hobart M; Augustine C; Zhang P; McQuade RD; Carson WH; Nyilas M; Sanchez R; Eriksson H
    J Clin Psychiatry; 2015 Sep; 76(9):1224-31. PubMed ID: 26301701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorder.
    Bauer M; Hefting N; Lindsten A; Josiassen MK; Hobart M
    Acta Neuropsychiatr; 2019 Feb; 31(1):27-35. PubMed ID: 30223911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: Results from a post-hoc analysis of two randomised controlled trials.
    McIntyre RS; Weiller E; Zhang P; Weiss C
    J Affect Disord; 2016 Sep; 201():116-23. PubMed ID: 27208498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning.
    Fava M; Okame T; Matsushima Y; Perry P; Weiller E; Baker RA
    Int J Neuropsychopharmacol; 2017 Jan; 20(1):22-30. PubMed ID: 27784751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment.
    Weisler RH; Ota A; Tsuneyoshi K; Perry P; Weiller E; Baker RA; Sheehan DV
    J Affect Disord; 2016 Nov; 204():40-7. PubMed ID: 27322768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of brexpiprazole as adjunctive treatment in major depressive disorder: overview of four short-term studies.
    Thase ME; Zhang P; Weiss C; Meehan SR; Hobart M
    Expert Opin Pharmacother; 2019 Oct; 20(15):1907-1916. PubMed ID: 31290344
    [No Abstract]   [Full Text] [Related]  

  • 10. Adjunctive Brexpiprazole and Functioning in Major Depressive Disorder: A Pooled Analysis of Six Randomized Studies Using the Sheehan Disability Scale.
    Hobart M; Zhang P; Weiss C; Meehan SR; Eriksson H
    Int J Neuropsychopharmacol; 2019 Mar; 22(3):173-179. PubMed ID: 30508090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double-blind (BLESS) study.
    Kato M; Shiosakai M; Kuwahara K; Iba K; Shimada Y; Saito M; Isogai Y; Sekine D; Aoki K; Koga N; Higuchi T
    Psychiatry Clin Neurosci; 2024 Feb; 78(2):113-122. PubMed ID: 37933521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
    El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of adjunctive brexpiprazole on the core symptoms of major depressive disorder: A post hoc analysis of two pooled clinical studies.
    Nelson JC; Weiller E; Zhang P; Weiss C; Hobart M
    J Affect Disord; 2018 Feb; 227():103-108. PubMed ID: 29055257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.
    Bauer M; Pretorius HW; Constant EL; Earley WR; Szamosi J; Brecher M
    J Clin Psychiatry; 2009 Apr; 70(4):540-9. PubMed ID: 19358791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brexpiprazole as Adjunctive Treatment for Major Depressive Disorder Following Treatment Failure With at Least One Antidepressant in the Current Episode: a Systematic Review and Meta-Analysis.
    Kishi T; Sakuma K; Nomura I; Matsuda Y; Mishima K; Iwata N
    Int J Neuropsychopharmacol; 2019 Nov; 22(11):698-709. PubMed ID: 31350882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Adjunctive Brexpiprazole on Individual Depressive Symptoms and Functioning in Patients With Major Depressive Disorder and Anxious Distress: Post Hoc Analysis of Three Placebo-Controlled Studies.
    McIntyre RS; Bubolic S; Zhang Z; MacKenzie EM; Therrien F; Miguelez M; Boucher M
    J Clin Psychopharmacol; 2024 Mar-Apr 01; 44(2):133-140. PubMed ID: 38421922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Irritability: An Exploratory Study.
    Fava M; Ménard F; Davidsen CK; Baker RA
    J Clin Psychiatry; 2016 Dec; 77(12):1695-1701. PubMed ID: 27379823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.
    Berman RM; Marcus RN; Swanink R; McQuade RD; Carson WH; Corey-Lisle PK; Khan A
    J Clin Psychiatry; 2007 Jun; 68(6):843-53. PubMed ID: 17592907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder.
    Hobart M; Zhang P; Skuban A; Brewer C; Hefting N; Sanchez R; McQuade RD
    J Clin Psychopharmacol; 2019; 39(3):203-209. PubMed ID: 30946704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study.
    Davis LL; Ota A; Perry P; Tsuneyoshi K; Weiller E; Baker RA
    Brain Behav; 2016 Oct; 6(10):e00520. PubMed ID: 27781135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.